---
title: "Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 10-Q: FY2025 Q3 Revenue: USD 860.5 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264508875.md"
published_at: "2025-11-05T22:11:13.000Z"
---

# Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 10-Q: FY2025 Q3 Revenue: USD 860.5 M

Revenue: As of FY2025 Q3, the actual value is USD 860.5 M.

EPS: As of FY2025 Q3, the actual value is USD -0.41.

### BSI BioSpin

-   **Revenue**: $208.7 million for Q3 2025, compared to $233.0 million for Q3 2024.
-   **Operating Income**: $33.3 million for Q3 2025, compared to $56.8 million for Q3 2024.

### BSI CALID

-   **Revenue**: $312.7 million for Q3 2025, compared to $279.4 million for Q3 2024.
-   **Operating Income**: $76.0 million for Q3 2025, compared to $58.7 million for Q3 2024.

### BSI NANO

-   **Revenue**: $266.5 million for Q3 2025, compared to $287.1 million for Q3 2024.
-   **Operating Income**: $23.5 million for Q3 2025, compared to $30.6 million for Q3 2024.

### BEST

-   **Revenue**: $72.6 million for Q3 2025, compared to $64.9 million for Q3 2024.
-   **Operating Income**: $7.0 million for Q3 2025, compared to $7.7 million for Q3 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $95.7 million for the nine months ended September 30, 2025, compared to $61.3 million provided in the same period in 2024.
-   **Net Cash Used in Investing Activities**: - $141.0 million for the nine months ended September 30, 2025, compared to - $1,696.7 million in the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $302.7 million for the nine months ended September 30, 2025, compared to $1,304.8 million in the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is implementing a corporate-wide restructuring plan to address macroeconomic challenges, drive cost efficiencies, and improve margins. This includes reducing headcount, consolidating facilities, and discontinuing certain product offerings, expected to be completed during 2026.
-   **Non-Core Business**: The company completed several acquisitions in 2025, including Recipe Chemicals + Instruments GmbH, enhancing capabilities in small molecule clinical diagnostic assays.

### Unique Metrics

-   **Goodwill Impairment**: The company recorded a goodwill impairment charge of $96.5 million during Q3 2025 due to the operating performance of certain reporting units and macroeconomic conditions.

### Related Stocks

- [BRKRP.US - Bruker Corp Pref Shares BRKRP 6.375 09/01/2028](https://longbridge.com/en/quote/BRKRP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Street View: 'Insatiable' luxury travel demand puts Marriott in a sweet spot | Marriott Internationalanticipates a 35% increase in fees from co-branded credit cards, driven by high demand for luxury  | [Link](https://longbridge.com/en/news/275625774.md) |
| Elon Musk backs Warren Buffett’s '5-minute' fix for America’s debt problem. But would it actually work? | “This is the way.” | [Link](https://longbridge.com/en/news/276005015.md) |
| AB Inbev CFO Fernando Tennenbaum: 2026 will hopefully be a more normal year on costs, we see further opportunities to expand margin | AB Inbev CFO Fernando Tennenbaum: 2026 will hopefully be a more normal year on costs, we see further opportunities to ex | [Link](https://longbridge.com/en/news/275819045.md) |
| K-shaped vs. E-shaped economy: Are you falling behind without even knowing it? | Explore the difference between K-shaped and E-shaped economies and how they affect top earners, middle earners, and lowe | [Link](https://longbridge.com/en/news/276000967.md) |
| Insights into PodcastOne Q3 Earnings | PodcastOne (NASDAQ:PODC) reported Q3 earnings on February 12, 2026, beating estimates with an EPS of $-0.01 compared to  | [Link](https://longbridge.com/en/news/275760771.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.